Telomir Pharmaceuticals reports new in vitro data on Telomir-1’s epigenetic activity

Telomir Pharmaceuticals has announced new in vitro data demonstrating that its lead drug candidate, Telomir-1, inhibits three members of the KDM5 histone demethylase family. These enzymes are implicated in silencing tumor suppressor genes and activating inflammatory pathways, processes associated with cancer and aging. The company previously reported that Telomir-1 also targets KDM2 and KDM6 families […] The post Telomir Pharmaceuticals reports new in vitro data on Telomir-1’s epigenetic activity appeared first on Longevity.Technology.